Female Reproductive System Adenocarcinoma

subtype

Identifier: CI-CAN-00002684
Entity page: /cancer/female-reproductive-system-adenocarcinoma ↗
Edges: 861

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Female Reproductive System Adenocarcinoma approved for …APPROVED_FORderived1 of 1
← approved for	Cyclophosphamidesmall molecule FDA (US) · approved · 2023-09-12 · adenocarcinoma of the ovary	—	approved	Ovarian Adenocarcinoma	1	Regulatory	openfda	graph →
Female Reproductive System Adenocarcinoma altered in cohorts of …ALTERED_IN

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

GNAS Mutation Palbociclib2 active / 3 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for GNAS in this cancerno approval record in this cancercontext: Pseudomyxoma Peritonei
BRAF V600E Vemurafenib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for BRAF in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
CUL1 Fusion Mitogen-Activated Protein Kinase Kinase Inhibitor0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for CUL1 in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
ERBB2 Amplification Trastuzumab0 active / 3 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Endometrial Serous Adenocarcinoma
MAP2K1 Q56_V60del Selumetinib0 active / 2 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for MAP2K1 in this cancerno approval record in this cancercontext: Ovarian Serous Adenocarcinoma
BRCA1 W1815X Olaparib13 active / 18 trials
Curatedlevel Dsensitivity· support 1civicObservedBRCA1 altered in 12% (37 / 316 cases)no approval record in this cancercontext: Ovarian Endometrioid Adenocarcinoma
CDK12 Loss-of-function Olaparib13 active / 18 trials
Curatedlevel Dsensitivity· support 1civicObservedCDK12 altered in 4.9% (20 / 405 cases)no approval record in this cancercontext: Ovarian Serous Adenocarcinoma
CCNE1 Amplification Akt Inhibitor MK22060 active / 2 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CCNE1 in this cancerno approval record in this cancercontext: Ovarian Serous Cystadenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Female Reproductive System Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 106show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 71 trials (22 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 55 trials (19 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 41 trials (8 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 39 trials (17 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 18 trials (13 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 17 trials (0 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 16 trials (12 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 15 trials (6 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 13 trials (7 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 13 trials (2 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 12 trials (0 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 9 trials (6 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 9 trials (7 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Adenocarcinoma	9	Observed	clinicaltrials	graph →

Female Reproductive System Adenocarcinoma studied in …STUDIED_INderived10 of 454show all (up to 200)
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 454 trials mapped (187 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 454 trials mapped (187 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 454 trials mapped (187 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 454 trials mapped (187 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 454 trials mapped (187 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 454 trials mapped (187 active)	—	—	Cervical Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 454 trials mapped (187 active)	—	—	Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped CURATED_BROADER · 454 trials mapped (187 active)	—	—	Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped CURATED_BROADER · 454 trials mapped (187 active)	—	—	Endometrial Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 454 trials mapped (187 active)	—	—	High-Grade Serous Ovarian Cancer	1	Observed	clinicaltrials	graph →